Search Results

On May 20, The Network’s government relations team and Maryland Oncology Hematology (MOH) attended a bill signing ceremony at the Maryland State Capitol. During the ceremony, Maryland Governor Wes Moore signed HB 1243 and SB 975 into law, which will permit cancer patients to access specialty drugs from community oncology practices and limit interference from…

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium and Longitudinal Prospective Study (MYLUNG Program: Part 3) Order-Set-Go: Increasing Biomarker Testing Rates in Patients with Non-small-cell Lung Cancer Through Use of Clinical Decision Support Tools (MYLUNG/23329/LUN 576) Brief Summary: This longitudinal study looks to quantify the testing timeline, operational barriers, and…

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer (FTH-PIK-201) MOA: PIKTOR is a combination of sapanisertib, an mTORC1 and 2 inhibitor, and serabelisib, a PI3Kα inhibitor. Key Eligibility Criteria: Histologically…

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) MOA: Subcutaneous amivantamab is a bispecific ab against EGF and cMET receptors, that is co-formulated with…

Ariuka Arya is a nurse practitioner with over six years of experience as a registered nurse across adult ICU, trauma, and cardiac testing settings. She received her Bachelor of Science in Nursing from George Mason University and her Master of Science in Nursing as a family nurse practitioner from the University of Alabama at Birmingham.…